LumiSort® intellectual property portfolio continues to
expand
TORONTO, May 1, 2013 /CNW/ - Microbix Biosystems Inc.
(TSX:MBX), a biotechnology company developing innovative biological
products and technologies including LumiSort®, a novel sperm sexing
technology for the global livestock industry, has been notified by
the United States Patent and
Trademark Office that its application for a new patent on LumiSort
technology has been allowed in the United
States. The patent is expected to issue within the next few
weeks.
Microbix' Lumisort technology is set to address the $1.5 billion artificial insemination market, with
the potential to grow that market by 100%. LumiSort is a
next-generation instrument-based (cytometric) technology for the
preparation of sex-selected sperm cell preparations that will
provide the artificial insemination industry with a 3-fold increase
in sperm cell yield and a 10-fold increase in the speed of
production, while increasing the fertility of the sexed sperm cell
product.
The most recent patent application, U.S.S.N. 13/214,699, was
filed in August 2011 as part of
Microbix' continuing program to develop intellectual property for
the LumiSort sperm sexing instrument and process.
Vaughn Embro-Pantalony, Chief
Executive Officer commented, "LumiSort is a completely new way to
approach sperm sexing, with significant advantages for the
livestock industry that will overtake existing, outdated methods.
We are committed to developing both our LumiSort instrument, and
our intellectual property portfolio, leading to the allowance of
this important second U.S. patent application with additional
patent applications pending. Microbix' patents underpin shareholder
value in the LumiSort investment and provide a solid basis of
exclusivity going forward."
Further information, including an animated video, on LumiSort
technology is available at http://lumisort.com.
About Microbix Biosystems Inc.
Microbix Biosystems Inc. specializes in the development of the
most advanced vaccine production technology and markets virology
and biological products worldwide. The Company has intellectual
property in large market biotherapeutic drugs, vaccine technologies
and animal reproduction technologies. Microbix supplies customers
in the U.S., Europe, and
Asia. Established in 1988,
Microbix is headquartered in Toronto.
Disclaimer
This press release contains forward-looking statements, which
are subject to risks and uncertainties that could cause actual
results to differ materially from those set forth in the
forward-looking statements including the risks associated with
commercializing the technologies, including sales which may not
reach sales targets or be made at all, there is no guarantee that
the Company will complete development of any technology and if it
does that it will perform to commercially exploitable levels, other
technologies may emerge before any technology developed by the
Company enters the market, royalty rates may not be achievable,
markets may not sustain demand for any product should world
economies shift significantly, market utilization rates may not be
reached, market value of products may vary, product launch dates
and market utilization timetables may not be met; risks associated
with the ability to license LumiSort to industry; risks associated
with failure to develop and commercialize LumiSort; non-adoption of
LumiSort; competition in the animal health and related markets;
reliance by Microbix on third parties for the development and
manufacture of LumiSort instrument; general economic conditions;
intellectual property risks including challenges to protecting the
Company's intellectual property rights, patents may not provide
adequate protection of the Company's intellectual property, may not
be successfully prosecuted and may be subject to challenge and
risks of infringement of third party rights; risks of operating in
foreign jurisdictions, including operating in countries with
evolving legal and economic infrastructure; high rates of
inflation; changes in taxation policies, and Microbix' ability to
attract and retain qualified employees and management. These
forward-looking statements represent the Company's judgment as of
the date of this press release. The Company disclaims any intent or
obligation to update these forward-looking statements.
SOURCE Microbix Biosystems Inc.
